Topical Sirolimus for Facial Angiofibroma in Tuberous Sclerosis Complex: A Case Series.

Autor: ETE, GAMPI¹ etegampi7@gmail.com, RAMTEKE, MANJEET², KAMATH, RATNAKAR R.³, FOGLA, NEHA¹, CHAVHAN, AARTI V.¹

Publikováno v: Journal of Clinical & Diagnostic Research. Nov2024, Vol. 18 Issue 11, p1-3. 3p.

Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database

Autor: Sreedevi Boggarapu, Steven L. Roberds, JoAnne Nakagawa, Eric Beresford

Publikováno v: Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-11 (2022)

Abstract Background Facial angiofibroma is the most predominant cutaneous manifestation of tuberous sclerosis complex (TSC), a rare autosomal dominant genetic disorder impacting the mechanistic target of rapamycin (mTOR). Facial angiofibroma can blee

Externí odkaz: https://doaj.org/article/f6b64bc6197140c8b3d01c834f6d1399

Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex

Autor: Takashi Hatano, Yuki Ohno, Yu Imai, Jun Moritake, Katsuhisa Endo, Mayumi Tamari, Shin Egawa

Publikováno v: Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-7 (2020)

Abstract Background Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder forming hamartomas throughout the body. Facial angiofibromas (FAs) occur in 75% of TSC patients, which are often enlarged, impairing the appearance of the face

Externí odkaz: https://doaj.org/article/b3a489e3da63424588307c6c0db8286c

Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex.

Autor: Ghazavi M; Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Taheri S; Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran., Sabzghabaee AM; Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Tavakolifard N; Department of Community and Family Medicine, Isfahan University of Medical Sciences, Isfahan, Iran., Yaghini O; Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Faghihi G; Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Afshar K; Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran., Abtahi-Naeini B; Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.; Pediatric Dermatology Division of Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran.

Publikováno v: Journal of research in pharmacy practice [J Res Pharm Pract] 2023 Aug 29; Vol. 11 (4), pp. 144-150. Date of Electronic Publication: 2023 Aug 29 (Print Publication: 2022).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.